Arbutin: Mechanism of its depigmenting action in human melanocyte culture

Journal of Pharmacology and Experimental Therapeutics

Volumn 276, Issue 2, 1996, Pages 765-769

  Maeda, Kazuhisa ^a   Fukuda, Minoru ^a  

^a SHISEIDO RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARBUTIN; MELANIN; MONOPHENOL MONOOXYGENASE;

ARTICLE; BASIDIOMYCETES; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; MELANOCYTE; PIGMENTATION;

ARBUTIN; BASIDIOMYCOTA; CELL SURVIVAL; CELLS, CULTURED; HUMANS; MELANINS; MELANOCYTES; MONOPHENOL MONOOXYGENASE; PIGMENTATION;

EID: 0030076508     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. AKIU, S., SUZUKI, Y., ASAHARA, T., FUJINUMA, Y. AND FUKUDA, M.: Inhibitory effect of arbutin on melanogenesis - Biochemical study using cultured B16 melanoma cells - (in Japanese). Jpn. J. Dermatol. 101: 609-613, 1991.
2. ARNDT, K. A. AND FITZPATRICK, T. B : Topical use of hydroquinone as a depigmenting agent. J. Am. Med. Assoc. 194: 117-119, 1965.
3. AROCA, P., SOLANO, F., SALTNAS, C., GARCIA-BORRON, J. C. AND LOZANO, J. A.: Regulation of the final phase of mammalian melanogenesis. The role of dopachrome tautomerase and the ratio between 5,6-dihydroxyindole-2-carboxylic acid and 5,6-dihydroxyindole. Eur. J. Biochem. 208: 155-163, 1992.
4. BENIGNI, J. D. AND MINNIS, R. L.: The synthesis of 5,6-dihydroxyindole and some of its derivatives (1). J. Heterocyclic Chem. 2: 387-392, 1965.
5. BLEEHEN, S. S.: Skin bleaching preparations. J. Soc Cosmet. Chem. 28: 407-412, 1977.
6. BREATHNACH, A. C., NAZZARO-PORRO, M. AND PASSI, S.: Azelaic acid therapy in disorders of pigmentation. Clin. Dermatol 7: 106-119, 1989.
7. CHEN, Y. M. AND CHAVIN, W.: Hydroquinone activation and inhibition of tyrosinase. In Pigment Cell: Vol. 3, ed. by V. Riley, pp. 105-112, Karger, Basel, 1976.
8. FITZPATRICK, T. B., ARNDT, K. A., EL-MOFTY, A. M. AND PATHAK, M. A.: Hydroquinone and psoralens in the therapy of hypermelanosis and vitiligo. Arch. Dermatol. 93: 589-600, 1966.
9. GRIFFITHS, C. E. M., FINKEL, L. J., DITRE, C. M., HAMILTON, T. A., ELLIS, C. N. AND VOORHEES, J. J.: Topical tretinoin (retinoic acid) improves melasma: A vehicle-controlled clinical trial. Br. J. Dermatol. 129: 415-421, 1993.
10. HANSSON, C.: 6-Hydroxy-5-methoxyindole-2-carboxylic acid in normal urine. Acta Dermatol. Venereol. (Stokh.) 64: 185-190, 1984.
11. HEARING, V. J. AND JIMÉNEZ, M.: Mammalian tyrosinase - The critical regulatory control point in melanocyte pigmentation. Int. J. Biochem. 19: 1141-1147, 1987.
12. IKEDA, T., SAI, M., FUJIWARA, K., HONJOH, T. AND HASHIZUME, S.: Serum-free medium for normal human melanocytes. Anim. Cell. Technol., Basic Appl. Aspects 6: 345-349, 1994.
13. ITO, S.: Reexamination of structure of eumelanin. Biochim. Biophys. Acta. 883: 155-161, 1986.
14. JIMBOW, K., OBATA, H., PATHAK, M. A. AND FITZPATRICK, T B : Mechanism of depigmentation by hydroquinone. J. Invest. Dermatol. 62: 436-439, 1974.
15. JIMBOW, K.: N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of melasma patients. Arch. Dermatol. 127: 1528-1534, 1991.
16. KANWAR, A. J., DHAR, S. AND KAUR, S.: Treatment of melasma with potent topical corticosteroids. Dermatology 188: 170, 1994.
17. KIMBROUGH-GREEN, C. K., GRIFFITHS, C. E. M., FINKEL, L. J., HAMILTON, T. A., BULENGO-RANSBY, S. M., ELLIS, C. N. AND VOORHEES, J. J.: Topical retinoic acid (tretinoin) for melasma in black patients: A vehicle-controlled clinical trial. Arch. Dermatol. 130: 727-733, 1994.
18. KLIGMAN, A. M. AND WILLIS, I : A new formula for depigmenting human skin. Arch Dermatol. 111: 40-48, 1975.
19. KÓRNOR, A. M. AND GETTINS, P.: Synthesis in vitro of 5,6-dihydroxyindole-2-carboxylic acid by dopachrome conversion factor from Cloudman S91 melanoma cells. J. Invest. Dermatol. 85: 229-231, 1985.
20. LAEMMLI, U. K.: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 227: 680-685, 1970.
21. LEONARD, L J., TOWNSEND, D. AND KING, R. A.: Function of dopachrome oxidoreductase and metal ions in dopachrome conversion in the eumelanin pathway. Biochemistry 27: 6156-6159, 1988.
22. MAEDA, K., TOMITA, Y., FUKUDA, M. AND TAGAMI, H.: Effects of staurosporine, PMA and A23187 on human melanocyte cultures with dibutyryl cyclic AMP. Br. J. Dermatol. 126: 118-124, 1992
23. MATSUDA, H., NAKAMURA, S., SHIOMOTO, H., TANAK, T. AND KUBO, M.: Pharmacological studies on leaf of Arctostaphylos uva-ursi (L.) Spreng. IV. Effect of 50% methanolic extract from Arctostaphylos uva-ursi (L.) Spreng (Bearberry leaf) on melanin synthesis. (in Japanese) Yakugaku-Zasshi 112: 276-282, 1992.
24. MISHIMA, Y., HATTA, S., OHYAMA, Y. AND INAZU, M.: Induction of melanogenesis suppression: Cellular pharmacology and mode of differential action. Pigment Cell Res. 1: 367-374, 1988.
25. MOSMANN, T.: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63, 1983.
26. NEERING, H.: Treatment of melasma (chloasma) by local application of steroid cream. Dermatologica 151: 349-353, 1975.
27. ORLOW, S. J., OSBER, M. P. AND PAWELEK, J. M.: Synthesis and characterization of melanins from dihydroxyindole-2-carboxylic acid and dihydroxyindole. Pigment Cell Res. 5: 113-121, 1992.
28. PALUMBO, A. D'ISCHIA, M., MISURACA, G. AND PROTA, G.: Effect of metal ions on the rearrangement of dopachrome. Biochim Biophys. Acta 925: 203-209, 1987
29. PAOLO, R.: Ascorbyl oleate and its application in skin depigmentation. Soap Perf Cosmetol. 41: 672-673, 1968.
30. PASSI, S. AND NAZZARO-PORRO, M.: Molecular basis of substrate and inhibitory specificity of tyrosinase. Br. J. Dermatol. 104: 659-665, 1981.
31. PAWELEK, J. M.: Dopachrome conversion factor functions as an isomerase. Biochem. Biophys. Res. Commun. 166: 1328-1333, 1990.
32. PAWELEK, J. M : After dopachrome? Pigment Cell Res. 4: 53-62, 1991.
33. PENNY, K. B., SMITH, C J. AND ALLEN, J C.: Depigmenting action of hydroquinone depends on disruption of fundamental cell processes. J. Invest. Dermatol. 82: 308-310, 1984.
34. SANCHEZ, N. P., PATHAK, M. A., SATO, S., FITZPATRICK, T B., SANCHEZ, J. L. AND MIHM, M. C., JR : Melasma: A clinical light microscopic, ultrastructural and immunofluorescence study. Am. Acad. Dermatol. 4: 698-710, 1981.
35. SEALY, R. C., HYDE, J. S., FELIX, C. C., MENON, I. A. AND PROTA, G.: Eumelanins and pheomelanins: Characterization by electron spin resonance spectroscopy. Science (Wash. DC) 217: 545-547, 1982.
36. SHIMANO, K.: Partial purification and kinetic studies of mammalian tyrosinase. Biochim. Biophys. Acta 62: 205-215, 1962.
37. SMITH, C. J., O'HARE, K. B. AND ALLEN, J. C : Selective cytotoxicity of hydroquinone for melanocyte-derived cells is mediated by tyrosinase activity but independent of melanin content. Pigment Cell Res 1: 386-389, 1988.
38. SUGAI, T.: Clinical effects of arbutin in patients with chloasma. (in Japanese) Hifu (Skin Res.) 34: 522-529,1992.
39. TAKASHIMA, H., NOMURA, H., IMAI, Y. AND MIMA, H.: Ascorbic acid esters and skin pigmentation Am. Perf. Cosmetol. 86: 29-36, 1971
40. TRIPATHI, R. K., HEARING, V. J., URABE, K., AROCA, P. AND SPRITZ, R A.: Mutational mapping of the catalytic activities of human tyrosinae. J. Biol. Chem. 267: 23707-23712, 1992.
41. VERALLO-ROWELL, V. M., VERALLO, V., GRAUPE, K., LOPEZ-VILLAFUERTE, L AND GARCIA-LOPEZ M.: Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta. Dermatol. Venereol. (Stockh.) 143: (Suppl.) 58-61, 1989.
42. WAKAMATSU, K AND ITO, S.: Preparation of eumelanin-related metabolites 5,6-dihydroxyindoles, 5,6-dihydroxyindole-2-carboxylic acid, and the o-methyl derivatives. Anal. Biochem. 170: 335-340, 1988.
43. WILCOX, D. E., PORRAS, A. G , HWANG, Y. T., LEECH, K., WINKLER, M. E. AND SOLOMON, E. I.: Substrate analogue binding to the coupled binuclear copper active site in tyrosinase. J. Am. Chem. Soc. 107: 4015-4027, 1985.